Pedro Barata, MD, MSc

Final Thoughts/Looking Forward

July 29th 2024

The Role of Chemotherapy in nccRCC Treatment

July 29th 2024

Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

July 29th 2024

World Health Organization (WHO) Classification Updates for Papillary RCC

July 29th 2024

Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

July 29th 2024

Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

July 29th 2024

Dr Voss Application of Updated KEYNOTE-564 Data

July 16th 2024

Martin Voss, MD, elaborates on the impact of the KEYNOTE-564 trial and its recently presented data on the management of renal cell carcinoma, highlighting how these findings have influenced treatment decisions and patient care strategies.

Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

July 16th 2024

Wenxin (Vincent) Xu, MD, presents the findings from the phase 3 CONTACT-03 trial, which compared the efficacy of atezolizumab in combination with cabozantinib versus cabozantinib alone in patients with inoperable advanced renal cell carcinoma who had previously received immune checkpoint inhibitor treatment.

Ongoing RCC Clinical Trials that may Impact Practice

July 8th 2024

Pedro Barata, MD, MSc, prompts the panel to share their opinions on which of the discussed clinical trials they find most promising and likely to influence clinical practice in the treatment of renal cell carcinoma.

Exciting Data and Trials in Progress from ASCO 2024

July 8th 2024

Elizabeth Wulff-Burchfield, MD, facilitates a conversation about several clinical trials, such as STELLAR-001 and KEYNOTE-426, which investigate various treatment approaches for renal cell carcinoma (RCC).

Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

July 2nd 2024

Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).

Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

July 2nd 2024

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).

Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

June 25th 2024

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

June 25th 2024

Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition.

Dr Barata on the Critical Updates for the Treatment of Advanced RCC in 2023

November 27th 2023

Pedro Barata, MD, MSc, discusses the biggest clinical trial updates to emerge for the treatment of patients with advanced renal cell carcinoma from the 2023 International Kidney Cancer Symposium.

Dr Barata on Staying Up to Date With Evolving Treatment Approaches in Kidney Cancer

August 28th 2023

Pedro Barata, MD, MSc, discusses the importance of staying up to date with evolving treatment approaches in kidney cancer.

Dr Barata on Immunotherapy Treatment and the Gut Microbiome in Kidney Cancer

August 25th 2023

Pedro Barata, MD, MSc, discusses important considerations regarding the relationship between immunotherapy treatment and the gut microbiome when treating patients with kidney cancer.

Dr Barata on the Relationship Between the Microbiome and Immunotherapy in RCC

July 26th 2023

Pedro Barata, MD, MSc, discusses the relationship between the gut microbiome and treatment with immunotherapy in patients with renal cell carcinoma.

Dr. Barata sobre el Ensayo EMBARK en Pacientes con Cáncer de Próstata no Metastásico de alto Riesgo y Sensible a Hormonas.

June 26th 2023

Pedro Barata, MD, MSc, discusses the importance of the phase 3 EMBARK trial in patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Dr. Barata sobre las Necesidades no Cubiertas de los Pacientes con Cáncer de Próstata

June 26th 2023

Pedro Barata, MD, MSc, discusses remaining unmet needs for patients with prostate cancer.